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Summary~ Mutation of the p53 gene is reported to be of prognostic importance in colorectal carcinomas.
Immunohistochemical staining of the accumulated p53 gene product may be a simple alternative for p53
mutation analysis. Previous studies addressing the prognostic importance of p53 expression. however, yielded
contradictory results. Therefore, we evaluated the importance of p53 expression as a marker for long-term
prognosis in a well-characterised study population of 109 colorectal carcinomas. After antigen retrieval with
target unmasking fluid (TUF). immunostaining of p53 was performed with both monoclonal antibody D07
and polyclonal antibody CMI. Objective quantification of the p53 signal was assessed by a computerised
image analyser. p53 expression was higher in non-mucinous tumours than in mucinous tumours (p53 labelling
index = 30% and 17% respectively, P = 0.05), and in metastatic tumours compared with non-metastatic
tumours (p53 labelling index = 37% and 22% respectively, P = 0.05). Other histopathological features were
not related to p53 expression. In multivariate analysis, Dukes' stage (P = 0.02) and histological grade
(P = 0.05) stood out as independent markers for prognosis. p53 expression was not an independent marker for
prognosis. At present. p53 expression is not a useful marker for long-term prognosis. Further insight into the
relationship between p53 mutations and p53 expression is needed to elucidate more precisely the clinical
relevance of p53 alterations.
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The p53-suppressor gene is the most frequently altered gene
in solid human malignancies (reviewed in Lane, 1992; Levine,
1992a, 1992b; Oren, 1992; Vogelstein and Kinzler, 1992). It is
located on the short arm of chromosome 17 in the region
17pl3 and encodes a 53 kDa nuclear phosphoprotein that
serves as a transcription factor (Kern et al., 1992; El-Deiry et
al., 1993). The p53 protein indirectly regulates cell growth
and inhibits cells with mutagenic damage from entering the
S-phase by arresting the cell cycle in GI, during which DNA
repair can proceed.
In colorectal cancer, p53 mutations are frequently accom-
panied by allelic loss of 17p (Baker et al., 1989; Rodrigues et
al., 1990). Both p53 mutations and allelic deletion of 17p
occur late in tumour progression (Baker et al., 1990) and are
reported to have prognostic value after surgery (Kern et al.,
1989; Laurent-Puig et al., 1992; Offerhaus et al., 1992;
Hamelin et al., 1994). However, both detection of p53 muta-
tions at the DNA level and detection of allelic deletion of
17p by restriction fragment length polymorphism (RFLP)
analysis are cumbersome procedures and therefore not feasi-
ble in routine diagnosis.
Recent reports describe a strong relation between p53 gene
mutations and mutant p53 protein expression (Rodrigues et
al., 1990; de Angelis et al., 1993; Baas et al., 1994). The
mutant p53 protein is characterised by a conformational
change resulting in prolonged half-life and stability, enabling
its detection by routine immunohistochemical (IHC) techni-
ques (Finlay et al., 1988). Therefore, immunostaining of the
p53 protein may be an important surrogate test for p53
mutation analysis.
In solid neoplasms including carcinomas of the breast
(Barnes et al., 1993), stomach (Martin et al., 1992; Starzyn-
ska et al., 1992), lung (Quinlan et al., 1992), ovary (Bosanr et
al., 1993) and pancreas (DiGuiseppe et al., 1994), p53 expres-
sion has been correlated with shortened survival. In colorec-
tal carcinomas, however, a correlation between survival and
nuclear p53 expression has not been consistently observed
(Scott et al., 1991; Remvikos et al., 1992; Starzynska et al.,
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1992; Sun et al., 1992; Yamaguchi et al.. 1992; Bell et al.,
1993; Bosari et al., 1994; Nathanson et al., 1994). The con-
tradictory results of these studies might be partly due to the
variability in IHC techniques used. Moreover, most follow-
up studies lacked statistical power owing to relatively small
patient populations or limited follow-up periods.
Therefore, in this study we analysed the value of p53
protein expression for long-term prognosis in a large, well-
characterised study population with over 20 years of follow-
up. p53 expression was evaluated by two different anti-p53
antibodies, which in a previous study stood out as being
most accurate for p53 protein detection and association with
p53 gene mutation (Baas et al.. 1994). p53 expression was
objectively scored by a computerised image analyser. In addi-
tion, we evaluated the relationship between p53 expression
and other histopathological parameters known to be of
importance in colorectal cancer.
Materia and methods
Stud) population andfollow-up
The original study population consisted of 155 patients with
colorectal carcinoma, operated on between 1967 and 1974 in
the University Hospital of Leiden. The study population had
previously undergone extensive research for a large number
of histopathological parameters which have a bearing on
tumour biology and prognosis (Bloem. 1983; Offerhaus et al.,
1991). For the present p53 immunostudy. tissue blocks were
available from 109 patients only. These patients did not differ
significantly from the original 155 with respect to age, sex or
the histopathological parameters. Histopathological para-
meters were determined by review of slides; location of the
tumour and macroscopic aspect, together with the patient
characteristics, were collected from the medical records by
review of charts.
In the p53-tested cohort of 109 patients, there were 56 men
and 53 women; the median age was 66 years (mean age 65
years, s.d. = 10 years, range 25-96 years). Twenty-two
tumours were located in the caecum or ascending colon, eight
in the transverse colon or splenic flexure, 46 in the descend-
ing colon or sigmoid and 33 tumours in the rectum. Tumoursp53 p in.- 'mlau- cudImi
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were staged according to the modified Dukes' classification
(Dukes, 1932; Turnbull et at., 1%7). Eighteen patets had a
Dukes' A carcoma (confired within the muularis propria),
61 patients had a Dukes' B carcinoma (extension through the
muscularis propria into the pericolic fat), 27 patients had a
Dukes' C carcinoma (positive regional lymph nodes without
distant metastases), and three patients had a Dukes' D car-
cinoma (either invasion of adjacent organs or evidence of
distant metastases). Twenty carcinomas were wel
differentiated, 67 were moderately differentiated and 22 were
poorly differentiated. Twenty-nine of the 109 tumours were
mucinous carcinomas (defined as at lat 30% of the volume
being occupied by muce lakes) (Mecklin et al., 1986). Of
those cases in which the macroscopic aspect was reliably
reported, 34 tumours showed exophytic growth and 55
tumours showed ulcerative growth. Fourteen tumours showed
'Crohn's-like' lymphocytic infiltration (Jass, 1986; Graham
and Appehtnan, 1990); in five cases the presce or absence of
lymphocytic infiltration was not evaluable. In 102 tumours
vasoinvasion of tumour cells was stdied by Van Gieson's
elastic stain and a factor VIII immunoperoxidase method for
the locaisation of endotheial cells (Muklai et al., 1980;
Muller et al., 1989; Offerhaus et al., 1991).
Follow-up was obtained through physician contact and
ended on 30 September 1993.
Immunohistochemistryforp53
On 109 paraffin-embedded specimens, routine immunostain-
ing was performed as reported previously (Baas et al., 1994),
using target unmasking fluid ('TUF; Kreatech Technology,
Amsterdam, The Netherlands) to enhance antigen retrieval
(van den Berg et al., 1993). Both rabbit polydonal antibody
CM1 (Novacastra laboratories, Newcastle upon Tyne, UK)
and mouse monoclonal antibody D07 (Dakopatts, Glotrup,
Denmark) against the p53 proten served as primary anti-
bodies (Baas et al., 1994). Further saining was with the
streptavdin-horseradish peroxidase (HRP)-ABC method
(Vectastain, Vector Laboratories, Burlingame, CA, USA),
and the chromagen was diaminobenzidine (DAB). Nulear
counterstainmg was performed with methyl green, enabing
p53 protein quantification by an image analyser (Baas et al.,
1994). Staining was controlled by omission of the primary
antibody.
Image anatysis
The CAS 200 image analysis system consit of a conven-
tional microscope with mounted television camera which is
linked to a computer and colour monitor. The ER/PR soft-
ware program enabled measurement of the total area of
positive nulcear staining in any selected microscopic field,
while the methyl green nuclear counterstain enabled measure-
ment of the total nuclear area. The ratio expressed as p53
labelling index (LI) gave an objective value for the percen-
tage of positive-staining nuclei. Baseline was set on p53-
negative normal mucosa. Negative stromal ekments were
controlled for by computing the mean p53 LI for each slide
in at least five representative fields at 400 x magification,
containing between 100 and 250 tumour nuclei (Baas et al.,
1994).
Statistical analysis
Statistical analysis was performed with JMP software (SAS
Institute, Cary, NC, USA). For survival analysis p53 expres-
sion was divided into three groups: (1) no nuclear p53 expres-
sion (LI<1l%), (2) low nuclear p53 expression (LI 1-30%),
and (3) high nuclear p53 expression (LI >30%). This tripar-
tition is based on the results ofprevious studies by our group
(Baas et al., 1994). Survival analysis for the other histo-
pathological parameters was assessd in both the p53-tested
cohort and the original cohort. One patient died within 30
days of surgery, and was therefore excuded from survival
analysis. Kaplan-Meier survival curves were alculated and
tested for significance by an univariate log-rank statistic.
These cures cluded only colorectal cancer-related deaths
as events. Deaths from other causes were treated as censored
events at time of occurrence. One patient was lost to follow-
up after 11.8 years and treated as a censored event from that
time. The independent prognostic value of parameters was
tested using the multivariate Cox regression model. Correla-
tion between p53 expression and histopathological para-
meters was tested using a t-test statistic or analysis of
variance (ANOVA) for multiple means.
Rets
p53 expression
p53 immunostaining was initially evaluated by conventional
light microscopy by two authors who were blinded for other
Table I p53 expression by immunostaining with MAb D07 and
PAb CM1
Estimation by Quwtificatwn by
conventional light computerised image
microscopy analysis
Percentage positive Labelling
cells D07 CM] index (%) D07
n % n % n %
<1 23 21 35 32 LI <1 31 28
1-30 17 16 25 23 LI 1-30 35 32
>30 69 63 49 45 LI >30 43 40
109 100 109 100 109 100
p53 protein positivity is evaluated by conventional light
micoscopy for MAb D07 and PAb CM1. p53 labelling index (LI) is
assessed on a computerised image analyser for p53 staining with
MAb D07.
Table n Association between IHC p53 expresson with MAb D07
and different histopathological parameters (mean p53 LI = the
average of the labeling inds in the gien subgroup)
Mean
p53-LI
n (%) P
sex
Male 56 27
Female 53 26 >0.2
Age (years)
<66 54 25
>66 55 28 >0.2
Location
Caccurn/ascending colon 22 21
Transverse colon/splenic flexure 8 28
Descending colon/sigmoid 46 29
Rectum 33 26 >0.2
Dukes' stage
A 18 26
B 61 21
C/D 30 37 0.05
Differentiation grade
Good 20 23
Moderate 67 27
Poor 22 27 >0.2
Mucus content
Mucinous 29 17
Non-mucinous 80 30 0.05
Macroscopic aspect
Exophytic 34 30
Ulerative 55 27 >0.2
Lymphocytic infiltration
Absent 90 27
Present 14 27 >0.2
Vasoinvasion
Absent 56 29
1 vessel 25 18
>1 vessel 21 34 0.13variables. p53 positivity was restricted to the nuclei of the
cells of malignant glands. Normal colonic mucosa expressed
no p53 protein. The results of the p53 immunostaining are
listed in Table I. A high correlation was found between the
results of the p53 detection with MAb D07 and pAb CM1
(P<0.0005). Therefore, objective quantification of p53 ex-
pression with a CAS 200 image analyser was performed only
on the D07-stained specimens.
Table I shows that the results of conventional evaluation
of p53 expression slightly differ from the amount of p53
protein when quantified by a computerised image analyser.
Thirty-one (28%) carcinomas showed no p53 expression
(LI <1%), 35 (32%) carcinomas showed low p53 expression
(LI 1-30%) and 43 (40%) carcinomas showed high p53
expression (LI> 30%).
p53 expression and histopathological parameters
The associations between p53 expression and histopatho-
logical parameters are listed in Table II. A weak significant
p53 aW hng-Sam proposis in caolarW
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overall increase in p53 expression with advancing Dukes'
stage was observed (P = 0.05). Mucinous tumours expressed
significantly less p53 protein than non-mucinous tumours
(P = 0.05). No significant difference in p53 expression with
regard to sex, age, macroscopic aspect, lymphocytic
infiltration or vasoinvasion by tumour cells was observed.
Results did not change significantly when low p53 expression
(LI 1-30%) was regarded as negative, or when a subdivision
into p53-negative (LI<1%) vs p53-positive (LI>1%) car-
cinomas was used.
Survival analysis
The results of the univariate survival analysis in the p53-
tested study group and the original complete cohort are listed
in Table III. The median period between surgery and death
or last physician contact was 7.3 years in both groups.
During follow-up, in the complete cohort 57 (37%) patients
died of colorectal carcinoma and 65 (42%) patients died of
causes unrelated to colorectal cancer. In the p53-tested
Table III Prognostic importance of histopathological parameters tested by univariate log-rank analysis
and the multivanrate Cox regression model. The risk ratios at each level use as a reference the previous
level, not the baseline level (RR = relative risk)
Complete cohort p53-tested cohort
10 year 10 year
n surv (%) P n surv (%) P
Univariate analysis
Sex
Male
Female
Age
<median
>median
Location
Caecum/ascending colon
Transverse colon/splenic flexure
Descending colonlsigmoid
Rectum
Dukes' stage
A
B
C D
Differentiation grade
Good
Moderate
Poor
Mucus content
Mucinous
Non-mucinous
Macroscopic aspect
Exophytic
Ulcerative
Lymphocytic infiltration
Absent
Present
Vasoinvasion
Absent
1 vessel
>1 vessel
p53 expression (%)
LI <I
LI 1-30
LI >30
Multivariate analysis
Dukes' stage
A
B
C/D
Differentiation grade
Well
Moderate
Poorly
81 56
73 62
77 60
77 58
31
12
64
47
28
90
36
27
95
32
59
57
62
54
82
61
37
76
60
41
42 64
112 57
47 73
77 54
120 54
26 75
74
34
25
60
57
35
55 55
>0.2 53 59
54 58
>0.2 54 56
22
8
45
>0.2 33
18
61
<0.001 29
20
66
0.005 22
58
63
53
58
73
60
41
74
57
40
29 73
>0.2 79 51
34 71
0.04 55 51
90 54
0.04 14 63
56
25
0.03 21
64
67
38
31 45
35 74
43 52
n RR P n RR
28
90
36
27
95
32
1.0
2.3
2.1
1.0
1.6
1.9
18
61
<0.001 29
20
66
0.01 22
1.0
1.5
1.9
1.0
1.5
1.9
>0.2
>0.2
>0.2
0.03
0.04
0.2
0.13
>0.2
0.08
0.08
p
0.02
0.05p53ud I iner preg- uotin~ awcual
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cohort these numbers were 42 (39%) and 48 (44%) respec-
tively.
In the complete cohort, increase in Dukes' stage (Figure
la), poorer grade of differentiation, ulcerative growth, lym-
phocytic infiltration and vasoinvasion was related to worse
prognosis. In the smaller p53 study subset, only Dukes' stage
(Figure lb) and grade of differentiation reained significnt.
The amount of p53 expression in carcinomas showed a ten-
dency towards an association with patient survival (P =
0.08), but the pattern of this relationship is difficult to inter-
pret: the highest and lowest p53 categories showed the poor-
est survival, whereas the intermediate p53 category showed
the best prognosis (Figure ic).
In the complete cohort, multivanate analysis showed that
only Dukes' stage (P = <0.001) and differentiation grade
(P = 0.01) were independent markers for prognosis. These
parameters were also independent predictors of prognosis in
the smaler p53-tested cohort (Dukes' stage, P = 0.02;
differentiation grade, P = 0.05) (Table III).
The prognosis after seemingly curative resection ofcolorectal
carcinoma depends largely on the absence or presence of
occult metastases, often accounting for mortality. Prediction
of outcome is currently based mainly on the stage ofcolorec-
tal carcinoma at time of resection. However, patients with
tumours of the same stage often show dramatically different
outcome. Therefore, more specific prognostic markers would
provide a rationale to adjust different therapeutic approaches.
Alterations ofthe p53 tumour-suppressor gene are potentially
such a marker (Hamelin et al., 1994), and immunostaining of
the p53 protein product could be a valuable test for p53 gene
alterations (Rodrigues et al., 1990; de Angels et al., 1993;
Baas et al., 1994).
Previous studies addressing the prognostic value of p53
were mostly restricted to short-term follow-up, and in partic-
ular the IHC studies yielded variable results (Table IV). This
variability might come from several causes. First of all, these
study groups may not always be comparable. Moreover, the
use ofvarious antibodies against different epitopes ofthe p53
protein, and sometimes the use of antigen retrieval systems,
may also account for some of the variability in the percen-
tages of p53 positivity seen among the different studies
(Table IV) (van den Berg et al., 1993; reviewed in Wynford-
Thomas, 1992; Hall and Lane, 1994). We previously evalua-
ted various procedures and six different p53 antibodies in
relationship with underlying p53 changes and selected the
two most accurate procedures for p53 protein detection for
use in this study (Baas et al., 1994). Objective quantification
of p53 expression was achieved by use of a computerised
image analyser. Opfimised IHC techniques combined with
computerised quantification yielded p53 positivity in 72% of
the carcinomas (Table I), a percentage that exceeds that ofall
previous studies (Table IV).
In our study, p53 expression was higher in metastatic
carcinomas (LI = 37%) than in non-metastatic Dukes' B car-
cinomas (LI = 21%). However, this phenomenon is not con-
sistently observed in other studies (Campo et al., 1991; Scott
et al., 1992; Purdie et al., 1991; Remvikos et al., 1992;
Starzynska et al., 1992; Sun et al., 1992; Bell et al., 1993; de
Angelis et al., 1993; Bosari et al., 1994; Mulder et al., 1995).
As in other studies (Campo et al., 1991; Hanski et al., 1992),
mucinous carcinomas exhibited significntly less p53 protein
than non-mucinous carcinomas, suggesting more p53 muta-
tions in non-mucinous carcinomas. Together with other
molecular aspects (Kern et al., 1989; Laurent-Puig et al.,
1991) and similar findings in the ovary (Enomoto et al.,
1991), this finding suggests that mucinous tumours may be
biologically different. No correlation was found between p53
expression and the other histopathological parameters. In
this study, we did not observe a difference in p53 positivity
between right- and left-sided carcinomas. This contrasts with
some studies in which p53-positive tumours were predomin-
antly found in the distal part of the large bowel (Scott et al.,
1991; Remvikos et al., 1992; Starzynska et al., 1992; Bosari et
al., 1994), but is concordant with other studies (Purdie et al.,
1991; Hansii et al., 1992; Yamaguchi et al., 1992; Bell et al.,
1993; Nathanson et al., 1994). The other results fit in the
general picture derived from other studies (Campo et al.,
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Table IV Survey of recent studies addressing p53 expression in colorectal carcinomas (crc) by immunostaining. When more than one
antibody was evaluated, the antibody (Ab) yielding the highest staining percentage is listed. When studied, the importance for prognosis is
listed
Per cent of crc Follow-up in Prognostic value
expressing p53 Antigen Other antibodies years Univariate Multivariate
Reference (Ab) enhancement evaluated n Mean range P p
This study 72 (D07) TUP CMI 109 7.3b 0-28 NS NS
Starzynska et al. (1992) 46 (CM1) - 107 <I 0-1 <0.001
Bell et al. (1993) 45 (421) 240 1801 100 3 0-8 NS
Yamaguchi et al. (1992) 61 (1801) 100 3 0.5-4 0.01 <0.05c
Scott et al. (1991) 42 (421) 52 3 1-7 NS
Remvikos et al. (1992) 60 (240) 421 1801 78 3,5b 0-4 <0.05
Bosanr et al. (1993) 46 (1801) Saponin CM1 206 >5 5-9 <0.02 NS
Sun et al. (1992) 24 (CM1) 1801 293 ? 1-8 NS NS
Nathanson et al. (1994) 62 (1801) ARSd 84 ? 5-10 NS NS
'Target unmasking fluid. bMedian. cNo Dukes' stage included in multivanrate analysis. dAntigen retrieval system.
1991; Purdie et al., 1991; Scott et al., 1991; Hanski et al.,
1992; Remvikos et al., 1992; Starzynska et al., 1992; Yama-
guchi et al., 1992; Bell et al., 1993; de Angelis et al., 1993;
Kaklamanis et al., 1993; Bosari et al., 1994; Nathanson et al.,
1994).
Established markers for prognosis such as Dukes' stage
and differentiation grade were independently associated with
survival, validating this study population. In this long-term
follow-up study we found that nuclear p53 protein expression
is not related to outcome after surgery. This result is similar
to previous studies (Scott et al., 1991; Sun et al., 1992; Bell et
al., 1993; Nathanson et al., 1994). Yamaguchi et al. (1992)
reported p53 positivity to be of independent prognostic
importance, but in their multivariate analysis Dukes' stage
was not included. Both Bosari et al. (1994) and Sun et al.
(1992) found cytoplasmic p53 staining with PAb CM1 to be
of independent prognostic importance, but as in most other
studies no reliable cytoplasmic staining was found in our
study.
The lack of consistent prognostic value of nuclear p53
protein expression might indicate that the reported impor-
tance for prognosis of p53 mutation needs additional study
and/or that the relationship between immunostaining of p53
protein and p53 gene mutation might be too much con-
founded by other biological mechanisms and technical
caveats (reviewed in Wynford-Thomas, 1992; Hall and Lane,
1994).
In conclusion, this study indicates that, with current
methodology, p53 protein expression does not appear to
contribute to the prediction of long-term prognosis after
resection of colorectal carcinoma. We emphasise that further
insight into the relationship between p53 gene mutations and
p53 protein expression is needed to elucidate more precisely
their clinical relevance.
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